HomeComparePROG vs BTI

PROG vs BTI: Dividend Comparison 2026

PROG yields 226.12% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROG wins by $247.28M in total portfolio value
10 years
PROG
PROG
● Live price
226.12%
Share price
$0.88
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$247.32M
Annual income
$132,258,559.01
Full PROG calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — PROG vs BTI

📍 PROG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROGBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROG + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROG pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROG
Annual income on $10K today (after 15% tax)
$19,219.90/yr
After 10yr DRIP, annual income (after tax)
$112,419,775.16/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, PROG beats the other by $112,417,406.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROG + BTI for your $10,000?

PROG: 50%BTI: 50%
100% BTI50/50100% PROG
Portfolio after 10yr
$123.68M
Annual income
$66,130,672.83/yr
Blended yield
53.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

PROG
Analyst Ratings
2
Buy
2
Hold
1
Sell
Consensus: Buy
Price Target
$4.00
+352.2% upside vs current
Range: $4.00 — $4.00
Altman Z
-19.8
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROG buys
0
BTI buys
0
No recent congressional trades found for PROG or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROGBTI
Forward yield226.12%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$247.32M$37.7K
Annual income after 10y$132,258,559.01$2,786.64
Total dividends collected$234.58M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$4.00$40.00

Year-by-year: PROG vs BTI ($10,000, DRIP)

YearPROG PortfolioPROG Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$33,312$22,611.64$11,299$598.92+$22.0KPROG
2$106,039$70,395.43$12,794$703.91+$93.2KPROG
3$322,887$209,425.60$14,518$829.07+$308.4KPROG
4$941,469$595,979.98$16,513$978.64+$925.0KPROG
5$2,631,436$1,624,064.27$18,827$1,157.84+$2.61MPROG
6$7,057,984$4,242,346.63$21,518$1,373.12+$7.04MPROG
7$18,186,373$10,634,330.10$24,657$1,632.46+$18.16MPROG
8$45,068,370$25,608,951.52$28,329$1,945.74+$45.04MPROG
9$107,533,957$59,310,801.02$32,637$2,325.33+$107.50MPROG
10$247,319,893$132,258,559.01$37,708$2,786.64+$247.28MPROG

PROG vs BTI: Complete Analysis 2026

PROGStock

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Full PROG Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this PROG vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROG vs SCHDPROG vs JEPIPROG vs OPROG vs KOPROG vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.